<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36946374</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>23</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1525-6049</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Renal failure</Title><ISOAbbreviation>Ren Fail</ISOAbbreviation></Journal><ArticleTitle>Plasma soluble tumor necrosis factor receptor I as a biomarker of lupus nephritis and disease activity in systemic lupus erythematosus patients.</ArticleTitle><Pagination><StartPage>2174355</StartPage><MedlinePgn>2174355</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2174355</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1080/0886022X.2023.2174355</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">The goal of our study was to evaluate the potential role of sTNF-RI as a biomarker of renal involvement in SLE patients and active SLE.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">The study sample consisted of two cohorts. The discovery cohort included 16 SLE patients without renal involvement (non-LN), 60 lupus nephritis (LN) patients and 21 healthy controls (HCs) and the replication cohort included 18 SLE non-LN patients, 116 LN patients and 36 HCs.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">The sTNF-RI levels differed significantly in the discovery cohort. The plasma sTNF-RI levels were higher in LN patients than in non-LN patients (<i>p</i>&#x2009;=&#x2009;.009) and HCs (<i>p</i>&#x2009;=&#x2009;4&#x2009;&#xd7;&#x2009;10<sup>-6</sup>). Plasma sTNF-RI levels were significantly higher in non-LN patients than in HCs (<i>p</i>&#x2009;=&#x2009;.03). The finding was confirmed in independent replication cohort (LNs <i>vs</i>. non-LN, <i>p</i>&#x2009;=&#x2009;4.053&#x2009;&#xd7;&#x2009;10<sup>-7</sup>; LNs <i>vs</i>. HCs, <i>p</i>&#x2009;=&#x2009;2.395&#x2009;&#xd7;&#x2009;10<sup>-18</sup>; non-LN <i>vs.</i> HCs, <i>p</i>&#x2009;=&#x2009;2.51&#x2009;&#xd7;&#x2009;10<sup>-4</sup>). The plasma sTNF-RI levels were associated with disease activity, renal&#x2002;function in SLE patients and urine protein in LN patients. The multivariate analysis revealed that high sTNF-RI was an independent risk factor for renal involvement. The multivariate logistic regression results suggested that high TNF-RI, high systolic blood pressure, high serum creatinine, low C4 and positive anti-dsDNA were independent risks of active SLE patients. A nomogram was constructed based on the results of multivariate logistic regression analysis and it was practical in predicting the risk of the active SLE patients. Immunohistochemistry suggested that the expression of TNF-RI in the kidney was increased.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Plasma sTNF-RI might be a good biomarker of renal involvement and disease activity in SLE patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xin-Ran</ForeName><Initials>XR</Initials><AffiliationInfo><Affiliation>Nephrology Hospital, the First Affiliated Hospital of Zhengzhou University, Henan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Nephrology, Zhengzhou University, Henan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qi</LastName><ForeName>Yuan-Yuan</ForeName><Initials>YY</Initials><AffiliationInfo><Affiliation>Nephrology Hospital, the First Affiliated Hospital of Zhengzhou University, Henan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Nephrology, Zhengzhou University, Henan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Ya-Fei</ForeName><Initials>YF</Initials><AffiliationInfo><Affiliation>Nephrology Hospital, the First Affiliated Hospital of Zhengzhou University, Henan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Nephrology, Zhengzhou University, Henan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Nephrology Hospital, the First Affiliated Hospital of Zhengzhou University, Henan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Nephrology, Zhengzhou University, Henan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Zhan-Zheng</ForeName><Initials>ZZ</Initials><AffiliationInfo><Affiliation>Nephrology Hospital, the First Affiliated Hospital of Zhengzhou University, Henan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Nephrology, Zhengzhou University, Henan, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ren Fail</MedlineTA><NlmUniqueID>8701128</NlmUniqueID><ISSNLinking>0886-022X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018124">Receptors, Tumor Necrosis Factor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018124" MajorTopicYN="N">Receptors, Tumor Necrosis Factor</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">disease activity</Keyword><Keyword MajorTopicYN="N">lupus nephritis</Keyword><Keyword MajorTopicYN="N">tumor necrosis factor receptor</Keyword></KeywordList><CoiStatement>We declare that this study was conducted in the absence of any financial or commercial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36946374</ArticleId><ArticleId IdType="pmc">PMC10035946</ArticleId><ArticleId IdType="doi">10.1080/0886022X.2023.2174355</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Durcan L, O'Dwyer T, Petri M.. Management strategies and future directions for systemic lupus erythematosus in adults. Lancet. 2019;393(10188):2332&#x2013;2343.</Citation><ArticleIdList><ArticleId IdType="pubmed">31180030</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakes RW, Bae SC, Louthrenoo W, et al. . Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality. Arthritis Care Res. 2012;64(2):159&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">22052624</ArticleId></ArticleIdList></Reference><Reference><Citation>Almaani S, Meara A, Rovin BH.. Update on lupus nephritis. Clin J Am Soc Nephrol. 2017;12(5):825&#x2013;835.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5477208</ArticleId><ArticleId IdType="pubmed">27821390</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiriakidou M, Ching CL.. Systemic lupus erythematosus. Ann Intern Med. 2020;172(11):Itc81&#x2013;itc96.</Citation><ArticleIdList><ArticleId IdType="pubmed">32479157</ArticleId></ArticleIdList></Reference><Reference><Citation>Idborg H, Eketj&#xe4;ll S, Pettersson S, et al. . TNF-&#x3b1; and plasma albumin as biomarkers of disease activity in systemic lupus erythematosus. Lupus Sci Med. 2018;5(1):e000260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6018889</ArticleId><ArticleId IdType="pubmed">29955370</ArticleId></ArticleIdList></Reference><Reference><Citation>Gane JM, Stockley RA, Sapey E.. TNF-&#x3b1; autocrine feedback loops in human monocytes: the pro- and anti-Inflammatory roles of the TNF-&#x3b1; receptors support the concept of selective TNFR1 blockade in&#xa0;vivo. J Immunol Res. 2016;2016:1079851.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5055993</ArticleId><ArticleId IdType="pubmed">27747245</ArticleId></ArticleIdList></Reference><Reference><Citation>Borghi A, Verstrepen L, Beyaert R.. TRAF2 multitasking in TNF receptor-induced signaling to NF-&#x3ba;B, MAP kinases and cell death. Biochem Pharmacol. 2016;116:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">26993379</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharapova TN, Romanova EA, Soshnikova NV, et al. . Autoantibodies from SLE patients induce programmed cell death in murine fibroblast cells through interaction with TNFR1 receptor. Sci Rep. 2020;10(1):11144.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7340778</ArticleId><ArticleId IdType="pubmed">32636466</ArticleId></ArticleIdList></Reference><Reference><Citation>Adhya Z, El Anbari M, Anwar S, et al. . Soluble TNF-R1, VEGF and other cytokines as markers of disease activity in systemic lupus erythematosus and lupus nephritis. Lupus. 2019;28(6):713&#x2013;721.</Citation><ArticleIdList><ArticleId IdType="pubmed">31046570</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan EM, Cohen AS, Fries JF, et al. . The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25(11):1271&#x2013;1277.</Citation><ArticleIdList><ArticleId IdType="pubmed">7138600</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.</Citation><ArticleIdList><ArticleId IdType="pubmed">9324032</ArticleId></ArticleIdList></Reference><Reference><Citation>Weening JJ, D'Agati VD, Schwartz MM, et al. . The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004;65(2):521&#x2013;530.</Citation><ArticleIdList><ArticleId IdType="pubmed">14717922</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman DD, Iba&#xf1;ez D, Urowitz MB.. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">11838846</ArticleId></ArticleIdList></Reference><Reference><Citation>Levey AS, Bosch JP, Lewis JB, et al. . A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med. 1999;130(6):461&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pubmed">10075613</ArticleId></ArticleIdList></Reference><Reference><Citation>Levey AS, Stevens LA, Schmid CH, et al. . A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604&#x2013;612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2763564</ArticleId><ArticleId IdType="pubmed">19414839</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrauben SJ, Shou H, Zhang X, et al. . Association of multiple plasma biomarker concentrations with progression of prevalent diabetic kidney disease: findings from the chronic renal insufficiency cohort (CRIC) study. J Am Soc Nephrol. 2021;32(1):115&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7894671</ArticleId><ArticleId IdType="pubmed">33122288</ArticleId></ArticleIdList></Reference><Reference><Citation>Nowak N, Skupien J, Smiles AM, et al. . Markers of early progressive renal decline in type 2 diabetes suggest different implications for etiological studies and prognostic tests development. Kidney Int. 2018;93(5):1198&#x2013;1206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5911430</ArticleId><ArticleId IdType="pubmed">29398132</ArticleId></ArticleIdList></Reference><Reference><Citation>Froon AH, Bemelmans MH, Greve JW, et al. . Increased plasma concentrations of soluble tumor necrosis factor receptors in sepsis syndrome: correlation with plasma creatinine values. Crit Care Med. 1994;22(5):803&#x2013;809.</Citation><ArticleIdList><ArticleId IdType="pubmed">8181289</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergquist M, Samuelsson L, Larsson A, et al. . TNFR1, TNFR2, neutrophil gelatinase-associated lipocalin and heparin binding protein in identifying sepsis and predicting outcome in an intensive care cohort. Sci Rep. 2020;10(1):15350.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7501293</ArticleId><ArticleId IdType="pubmed">32948801</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G, Goeddel DV.. TNF-R1 signaling: a beautiful pathway. Science. 2002;296(5573):1634&#x2013;1635.</Citation><ArticleIdList><ArticleId IdType="pubmed">12040173</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Lamki RS, Wang J, Vandenabeele P, et al. . TNFR1- and TNFR2-mediated signaling pathways in human kidney are cell type-specific and differentially contribute to renal injury. FASEB J. 2005;19(12):1637&#x2013;1645.</Citation><ArticleIdList><ArticleId IdType="pubmed">16195372</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng YM, Thijs L, Zhang ZY, et al. . Glomerular function in relation to circulating adhesion molecules and inflammation markers in a general population. Nephrol Dial Transplant. 2018;33(3):426&#x2013;435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6018976</ArticleId><ArticleId IdType="pubmed">28992257</ArticleId></ArticleIdList></Reference><Reference><Citation>Niewczas MA, Pavkov ME, Skupien J, et al. . A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes. Nat Med. 2019;25(5):805&#x2013;813.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6508971</ArticleId><ArticleId IdType="pubmed">31011203</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SM, Yang S, Cha RH, et al. . Circulating TNF receptors are significant prognostic biomarkers for idiopathic membranous nephropathy. PLoS One. 2014;9(8):e104354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4123977</ArticleId><ArticleId IdType="pubmed">25098821</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatraju PK, Zelnick LR, Shlipak M, et al. . Association of soluble TNFR-1 concentrations with long-term decline in kidney function: the multi-ethnic study of atherosclerosis. J Am Soc Nephrol. 2018;29(11):2713&#x2013;2721.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6218870</ArticleId><ArticleId IdType="pubmed">30287518</ArticleId></ArticleIdList></Reference><Reference><Citation>Srivastava A, Schmidt IM, Palsson R, et al. . The associations of plasma biomarkers of inflammation with histopathologic lesions, kidney disease progression, and mortality-the Boston kidney biopsy cohort study. Kidney Int Rep. 2021;6(3):685&#x2013;694.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7938082</ArticleId><ArticleId IdType="pubmed">33732983</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonoda Y, Gohda T, Suzuki Y, et al. . Circulating TNF receptors 1 and 2 are associated with the severity of renal interstitial fibrosis in IgA nephropathy. PLoS One. 2015;10(4):e0122212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4393287</ArticleId><ArticleId IdType="pubmed">25860248</ArticleId></ArticleIdList></Reference><Reference><Citation>Navarro JF, Mora-Fern&#xe1;ndez C.. The role of TNF-alpha in diabetic nephropathy: pathogenic and therapeutic implications. Cytokine Growth Factor Rev. 2006;17(6):441&#x2013;450.</Citation><ArticleIdList><ArticleId IdType="pubmed">17113815</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng CZ, Yan WW, Luo YL, et al. . Value of sTNF-R1 and linc0597 as indicators for disease activity and diagnosis of lupus nephritis. Eur Rev Med Pharmacol Sci. 2020;24(10):5582&#x2013;5591.</Citation><ArticleIdList><ArticleId IdType="pubmed">32495893</ArticleId></ArticleIdList></Reference><Reference><Citation>Aten J, Roos A, Claessen N, et al. . Strong and selective glomerular localization of CD134 ligand and TNF receptor-1 in proliferative lupus nephritis. J Am Soc Nephrol. 2000;11(8):1426&#x2013;1438.</Citation><ArticleIdList><ArticleId IdType="pubmed">10906156</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill GS, Delahousse M, Nochy D, et al. . Proteinuria and tubulointerstitial lesions in lupus nephritis. Kidney Int. 2001;60(5):1893&#x2013;1903.</Citation><ArticleIdList><ArticleId IdType="pubmed">11703608</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>